Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 8/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.54 |
| ▸ | RECQL | P46063 | 6/20 | 0.54 |
| ▸ | USP2 | O75604 | 3/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | FYN | P06241 | 2/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | BLM | P54132 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19361106 | 1.00 | KDM4E (0.54) | KDM4EHSD17B10ALOX15TDP1HIF1A | |
| SCHEMBL16367227 | 0.89 | KDM4E (0.53) | KDM4EHSD17B10ALOX15TDP1HIF1A | |
| SCHEMBL16367206 | 0.89 | KDM4E (0.53) | KDM4EHSD17B10ALOX15TDP1HIF1A | |
| SCHEMBL19361105 | 0.89 | KDM4E (0.53) | KDM4EHSD17B10ALOX15TDP1HIF1A | |
| SCHEMBL19361104 | 0.89 | KDM4E (0.53) | KDM4EHSD17B10ALOX15TDP1HIF1A | |
| SCHEMBL18159868 | 0.89 | KDM4E (0.53) | KDM4EHSD17B10ALOX15TDP1HIF1A | |
| Levodopa SCHEMBL18960581 | 0.85 | TDP1 (0.60) | KDM4EHSD17B10ALOX15TDP1HIF1A | |
| Levodopa SCHEMBL18960587 | 0.85 | TDP1 (0.60) | KDM4EHSD17B10ALOX15TDP1HIF1A | |
| Levodopa SCHEMBL2688586 | 0.85 | TDP1 (0.60) | KDM4EHSD17B10ALOX15TDP1HIF1A | |
| Melevodopa SCHEMBL28364800 | 0.83 | LCK (0.48) | KDM4EHSD17B10ALOX15TDP1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170182024-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PARKINSON'S DISEASE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-06-29 | — | — | US | disclosed |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20150011630-A1 | DIHYDROXYPHENYL NEUROTRANSMITTER COMPOUNDS, COMPOSITIONS AND METHODS | AUSPEX PHARMACEUTICALS, INC. | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011630-A1 | DIHYDROXYPHENYL NEUROTRANSMITTER COMPOUNDS, COMPOSITIONS AND METHODS | SLC18A2, COMT, SLC6A2 | KDM4E 856/4885HSD17B10 812/4885ALOX15 1153/4885 |
| US-20170182024-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PARKINSON'S DISEASE | PRLHR, PARK7, NLN | KDM4E 4345/4885HSD17B10 3746/4885ALOX15 540/4885 |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | PYGM, TNNC1, MUSK | KDM4E 3220/4885HSD17B10 1169/4885ALOX15 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.